NCT02230501

Brief Summary

Formerly, the investigators demonstrated in an uncontrolled proof-of principle study (NCT 01680926) that protein-rich meal replacement (PRMR) was successful in reducing daily insulin demand, HbA1c and weight in type 2 diabetes mellitus (T2DM) patients injecting \>100 IE insulin/day. The aim of the present study was to investigate in a randomized-controlled trial if PRMR is also effective in T2DM patients treated with oral antidiabetic medication or insulin. A second part of the study is an open-label registry for persons with type 2 diabetes, who will perform the lifestyle intervention with the stringent diet regime.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
300

participants targeted

Target at P75+ for not_applicable type-2-diabetes-mellitus

Timeline
Completed

Started Feb 2011

Longer than P75 for not_applicable type-2-diabetes-mellitus

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

February 1, 2011

Completed
3.6 years until next milestone

First Submitted

Initial submission to the registry

August 26, 2014

Completed
8 days until next milestone

First Posted

Study publicly available on registry

September 3, 2014

Completed
9.3 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 31, 2023

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

December 31, 2023

Completed
Last Updated

January 23, 2024

Status Verified

January 1, 2024

Enrollment Period

12.9 years

First QC Date

August 26, 2014

Last Update Submit

January 22, 2024

Conditions

Outcome Measures

Primary Outcomes (1)

  • HbA1c

    change in hemoglobin A1c

    12 weeks

Secondary Outcomes (9)

  • HbA1c

    1 year

  • body weight

    12 weeks and 1 year

  • blood pressure

    12 weeks and 1 year

  • cholesterol

    12 weeks and 1 year

  • fasting blood glucose

    12 weeks and 1 year

  • +4 more secondary outcomes

Study Arms (2)

moderate diet regimen

EXPERIMENTAL

Week 1-4: replacement of breakfast and dinner with 1g PRMR /kg normal weight (=height in cm-100), a protein-rich lunch was allowed Week 5-12: replacement of dinner For this arm a local subgroup (n=55) and a nation-wide subgroup (n=100) is planned.

Dietary Supplement: moderate diet regimen

stringent diet regimen

EXPERIMENTAL

Week 1: replacement of 3 main meals by 1g PRMR / kg normal weight (=height in cm - 100) Week 2-4: replacement of breakfast and dinner, a protein-rich lunch was allowed Week 5-12: replacement of dinner For this arm a local subgroup (n=55) and a nation-wide subgroup (n=100) is planned.

Dietary Supplement: stringent diet regimen

Interventions

stringent diet regimenDIETARY_SUPPLEMENT
Also known as: protein-rich meal replacement (PRMR), i.e Almased-Vitalkost (Almased Wellness GmbH, Bienenbüttel, Germany)
stringent diet regimen
moderate diet regimenDIETARY_SUPPLEMENT
Also known as: protein-rich meal replacement (PRMR), i.e Almased-Vitalkost (Almased Wellness GmbH, Bienenbüttel, Germany)
moderate diet regimen

Eligibility Criteria

Age25 Years - 79 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Type 2 diabetes mellitus
  • HbA1c \> 7,5%
  • Body Mass Index (BMI) ≥ 27,5 kg/m2

You may not qualify if:

  • acute infections
  • severe diseased with hospital stay during the last 3 months
  • chronic diseases
  • chemotherapy or cortisone treatment
  • weight loss of more than 2 kg per week during the last month
  • smoking cessation during the last 3 months or planned
  • weight-influencing medication
  • pregnancy, breast-feeding or lack of contraception
  • high-level physical activity of more than 1h per day
  • incompatibility with components of the PRMR
  • participation in an other study during the last 6 months

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

West German Centre of Diabetes and Health

Düsseldorf, 40591, Germany

Location

MeSH Terms

Conditions

Diabetes Mellitus, Type 2

Condition Hierarchy (Ancestors)

Diabetes MellitusGlucose Metabolism DisordersMetabolic DiseasesNutritional and Metabolic DiseasesEndocrine System Diseases

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
TRIPLE
Who Masked
CARE PROVIDER, INVESTIGATOR, OUTCOMES ASSESSOR
Masking Details
For the second part of the study, i.e. the open-label registry, 4000 subjects are anicipated.
Purpose
SUPPORTIVE CARE
Intervention Model
PARALLEL
Model Details: For the second part of the study, i.e. the open-label registry, there ist no randomization.
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Principal investigator

Study Record Dates

First Submitted

August 26, 2014

First Posted

September 3, 2014

Study Start

February 1, 2011

Primary Completion

December 31, 2023

Study Completion

December 31, 2023

Last Updated

January 23, 2024

Record last verified: 2024-01

Locations